Cargando…
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
BACKGROUND: Dosimetry in [(177)Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to determine the absorbed dose in organs and tumor lesions after [(177)Lu]Lu-PSMA-617 therapy, by reducing the imaging time p...
Autores principales: | Peters, Steffie M. B., Mink, Maaike C. T., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873880/ https://www.ncbi.nlm.nih.gov/pubmed/36692682 http://dx.doi.org/10.1186/s13550-023-00952-z |
Ejemplares similares
-
Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021) -
[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021) -
Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023) -
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020) -
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)